Back to search

Spain· ES:00152005

INFANRIX HEXA POLVO Y SUSPENSION PARA SUSPENSION INYECTABLE

A medicinal product containing vacuna anti hepatitis b + h.influenzae b + difteria + tétanos + tos ferina + polio, registered in Spain by Glaxosmithkline Biologicals.

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedINFANRIX HEXA POLVO Y SUSPENSION PARA…ATC—REGISTER NO.ES:00152005PACKS LISTED0CHECKEDSeptember 12, 2026

The record

At a glance

AEMPS CIMA (Spain)
Active substance
vacuna anti hepatitis B + H.influenzae b + difteria + tétanos + tos ferina + polio
Manufacturer
Glaxosmithkline Biologicals
Country
Spain (ES)
ATC code
—
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c11ce048-7cb9-43b7-b0d7-b95b312c703e
GET /v1/drugs/c11ce048-7cb9-43b7-b0d7-b95b312c703e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Medicamento Sujeto A Prescripción Médica",
  "estado": "{\"aut\":985129200000}",
  "nregistro": "00152005",
  "substance": "vacuna anti hepatitis B + H.influenzae b + difteria + tétanos + tos ferina + polio"
}

See everything about vacuna anti hepatitis b + h.influenzae b + difteria + tétanos + tos ferina + polio.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.